Search research articles
Contact Us
Filters
Showing results (91-100 of 188) with videos related to
Page
of 19
Sort By:
Cancer Biology & Therapy
|
June 14, 2013
Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines
Aisling Pierce, Patricia M McGowan, Maura Cotter, et al.
Cancer Chemotherapy and Pharmacology
|
January 16, 2024
Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells
Thamir M Mahgoub, Emmet J Jordan, Amira F Mahdi, et al.
The American Journal of Surgical Pathology
|
January 19, 2024
Prognostic Value of BAP1 Protein Expression in Uveal Melanoma
Susan Kennedy, Sally Owens, Laura Ivers, et al.
Oncoscience
|
January 17, 2015
Predictive biomarkers for dasatinib treatment in melanoma
Alex J Eustace, Susan Kennedy, Anne-Marie Larkin, et al.
International Journal of Cancer
|
May 28, 2011
MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis
Serena Germano, Susan Kennedy, Sweta Rani, et al.
Endocrine-Related Cancer
|
February 19, 2017
Vitamin D receptor as a target for breast cancer therapy
Alyson Murray, Stephen F Madden, Naoise C Synnott, et al.
Cellular Immunology
|
July 25, 2017
Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines
Denis M Collins, Kathy Gately, Clare Hughes, et al.
Plos One
|
May 12, 2017
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer
Denis Collins, Wolfgang Jacob, Juan Miguel Cejalvo, et al.
Pharmaceuticals (Basel, Switzerland)
|
March 28, 2026
Physiologically-Based Pharmacokinetics of Ribociclib Drug-Drug Interactions and Organ Impairment Pharmacokinetics in Early Breast Cancer
Yan Ji, Felix Huth, Craig Wang, et al.
International Journal of Oncology
|
May 13, 2017
Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells
Martina S J McDermott, Alexandra Canonici, Laura Ivers, et al.
Page
of 19
Search research articles
Search
Showing results (91-100 of 188) with videos related to
Sort By:
Page
of 19
Cancer Biology & Therapy
|
June 14, 2013
Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines
Aisling Pierce, Patricia M McGowan, Maura Cotter, et al.
Cancer Chemotherapy and Pharmacology
|
January 16, 2024
Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells
Thamir M Mahgoub, Emmet J Jordan, Amira F Mahdi, et al.
The American Journal of Surgical Pathology
|
January 19, 2024
Prognostic Value of BAP1 Protein Expression in Uveal Melanoma
Susan Kennedy, Sally Owens, Laura Ivers, et al.
Oncoscience
|
January 17, 2015
Predictive biomarkers for dasatinib treatment in melanoma
Alex J Eustace, Susan Kennedy, Anne-Marie Larkin, et al.
International Journal of Cancer
|
May 28, 2011
MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis
Serena Germano, Susan Kennedy, Sweta Rani, et al.
Endocrine-Related Cancer
|
February 19, 2017
Vitamin D receptor as a target for breast cancer therapy
Alyson Murray, Stephen F Madden, Naoise C Synnott, et al.
Cellular Immunology
|
July 25, 2017
Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines
Denis M Collins, Kathy Gately, Clare Hughes, et al.
Plos One
|
May 12, 2017
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer
Denis Collins, Wolfgang Jacob, Juan Miguel Cejalvo, et al.
Pharmaceuticals (Basel, Switzerland)
|
March 28, 2026
Physiologically-Based Pharmacokinetics of Ribociclib Drug-Drug Interactions and Organ Impairment Pharmacokinetics in Early Breast Cancer
Yan Ji, Felix Huth, Craig Wang, et al.
International Journal of Oncology
|
May 13, 2017
Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells
Martina S J McDermott, Alexandra Canonici, Laura Ivers, et al.
Page
of 19